Forward suing Biogen Idec in Germany
Forward Pharma A/S (Copenhagen, Denmark) filed suit in a German court alleging that German sales of Tecfidera dimethyl fumarate from Biogen Idec Inc. (NASDAQ:BIIB) infringe Forward's German utility model, which essentially is a patent whose claims have not been examined by a patent office. Forward said it expects a decision from the Regional Court in Dusseldorf, Germany, by YE15.
Forward Pharma alleges that according to utility model DE 20 2005 022 112, the company's consent is required to sell MS drugs in Germany that are administered at a daily dose of 480 mg and contain dimethyl fumarate as the sole active pharmaceutical ingredient. It is seeking damages and compensation based on Biogen's German Tecfidera sales between July 5, 2014, and Oct. 7, 2015, as well as compensation for unjust enrichment from April 24. ...